{"id":13,"date":"2024-06-08T08:42:10","date_gmt":"2024-06-07T23:42:10","guid":{"rendered":"http:\/\/evermed.jp\/?page_id=13"},"modified":"2024-09-17T16:18:55","modified_gmt":"2024-09-17T07:18:55","slug":"about-us","status":"publish","type":"page","link":"http:\/\/evermed.jp\/?page_id=13","title":{"rendered":"About US"},"content":{"rendered":"\n
\n
\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n

Company Plofile<\/em><\/h1>\n\n\n\n
Company Name<\/strong><\/td>EVerMed Inc.<\/strong><\/td><\/tr>
Date of establishment<\/strong><\/td>April, 15, 2024<\/strong><\/td><\/tr>
Location<\/strong><\/td>3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, Japan.<\/strong><\/td><\/tr>
Board<\/strong><\/td>Naoto Matsuda<\/strong>
Yu Fujita<\/strong>
Daisuke Niwa<\/strong>
Ted Yamamoto (Auditor)<\/strong><\/td><\/tr>
Contact<\/strong>\u3000<\/td>info[@]evermed.jp<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
\n
<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n

Founder<\/em><\/h1>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Yu Fujita MD,PhD<\/strong><\/p>\n\n\n\n

Dr. Yu Fujita graduated from the Jikei University School of Medicine, Tokyo, in 2007 (M.D.). Following his clinical internship, he joined the lab of Dr. Takahiro Ochiya, a global pioneer in the field of extracellular vesicles (EVs), at the National Cancer Center Research Institute as a Research Resident from 2012. He earned his Ph.D. in Medicine from the Jikei University in 2015, specializing in RNAi drug delivery research. From 2015 to 2018, he served as a postdoctoral fellow at UCSD and the Sanford Burnham Institute in San Diego. Upon returning to Tokyo, he focused on the field of EVs in lung biology as a physician-scientist. In 2020, he became a Principal Investigator (PI) of the Exosome Drug Development Research Lab in collaboration with industry partners at the Jikei University. Since October 2023, he has been appointed an Associate Professor in the Next-Generation Drug Discovery Research Division at the Research Center for Medical Sciences, the Jikei University School of Medicine. Dr. Fujita’s lab has made significant contributions to EV drug development research in Japan, aiming to pioneer first-in-class EV medicine through collaborative efforts with domestic and international companies. In 2024, he co-founded EVerMed to promote his science. He continues to practice as an internist specializing in respiratory medicine, providing ongoing patient care.<\/p>\n\n\n\n

<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Naoto Matsuda<\/strong><\/p>\n\n\n\n

After completing his master’s degree in organic synthesis chemistry at Waseda University, he joined Fujifilm Corporation in 1989, where he worked as an organic synthesis researcher, a project manager for color film product development, then as an engineer recruitment manager, and a pharmaceutical business project manager. After these diverse work experience, he was appointed the secretary general of the Forum for Innovative Regenerative Medicine, a Japanese industry association for regenerative medicine, and has since devoted himself to the fields of regenerative medicine and drug discovery venture businesses.<\/p>\n\n\n\n

In 2016, he founded Regcell Inc., a startup aiming for immune cell therapy, and in 2019, he founded NanoSuit Inc., which deals in reagents for electron microscope observation, and has also been supporting the founding and financing of more than ten startups so far. In 2024, he founded Evermed with Dr. Yu Fujita.<\/p>\n<\/div>\n<\/div>\n\n\n\n

Access<\/em><\/h1>\n\n\n\n